Victor Tieu

🗣️wahoo!!! my doctoral work is out online in @CellCellPress: authors.elsevier.com/c/1ie1VL7PXqPm4!! couldn't have done it without my two wonderful labs and co-advisors @stanleyqilab & @MackallLab we developed a new RNA-targeting CRISPR platform (MEGA) to engineer better T cell therapies...🧵

*in british accent* reprogramme ☕ T cell phenotype and function

so grateful for the opportunity to highlight our work on multiplexed transcriptome engineering & combinatorial screening for better CAR T cell therapies in the latest issue of @NatureRevCancer!! 📄: rdcu.be/dHbjn

We’re still in our BRAT summer by sharing our new RNA resources! Improved understanding of RNA over the years has led to huge developments, such as creating a COVID vaccine that saved millions of lives. Learn more in our new fact sheet! genome.gov/about-genomics…

@KipnissNathan THE ANGST

yes!! i've long suspected that this was the case since essentially all prior cas13d collateral cleavage studies were done in transfected cell lines. it's so great to see this important & rigorous study out – congrats to the team!!

Engineered CRISPR-Cas12a for higher-order combinatorial chromatin perturbations go.nature.com/3UTnSXM

when in new york

Bidirectional epigenetic editing reveals hierarchies in gene regulation go.nature.com/4apFU9q

Nature research paper: Engineered CD47 protects T cells for enhanced antitumour immunity go.nature.com/4bl7dmG

thanks @GenomeSeminars @harvardmed for inviting me to give a talk on MEGA recently!! really great opportunity for young scientists/first authors to present & discuss their work. seminars are weekly, totally free to attend (zoom), and recorded/posted here: gess.hms.harvard.edu

!!!!!

In summary, memory programming (but not TOO much memory) is a great thing for CAR T! FOXO1 is critical for mediating CAR T function and FOXO1 overexpression represents a broadly-applicable approach to enhance CAR T antitumor activity. The jury is still out on TCF1/TCF7. 13/

Check out the latest findings from PICI Center Director at @StanfordMed Crystal Mackall, MD, @MackallLab. The PICI-funded research suggests cell therapies for #cancer could see improvements with use of a new CRISPR RNA-editing platform called MEGA. Learn more in @CellCellPress

wow!! thank you @ACIR_org & lauren hitchings for the wonderful writeup and visual summary of our work!!

Lead author Victor Tieu, @stanleyqilab, Crystal Mackall @MackallLab & team discovered a way to potentially improve CAR T therapies using a CRISPR RNA-editing platform—Multiplexed Effector Guide Arrays (MEGA)—that boosts the cells’ ability to target tumors stanford.io/49LV20X

@DravenRane @CellCellPress @stanleyqilab @MackallLab thanks draven!!!!! 🥹✨

🗣️wahoo!!! my doctoral work is out online in @CellCellPress: authors.elsevier.com/c/1ie1VL7PXqPm4!! couldn't have done it without my two wonderful labs and co-advisors @stanleyqilab & @MackallLab we developed a new RNA-targeting CRISPR platform (MEGA) to engineer better T cell therapies...🧵

A CRISPR-Cas13d based platform MEGA enables safer, more controllable editing of T cells to enhance CAR T therapy via reversible, multiplexed gene knockdown without cutting genomic DNA. #NBThighlight cell.com/cell/abstract/…

SCI members Stanley Qi, Crystal Mackall & team pioneered MEGA, a #CRISPR RNA-editing tool enhancing #CARTcells precision against tumors. stanford.io/3TdepLd @stanleyqilab @MackallLab

@pdhsu senpai noticed me 👀

Awesome work using multiplexed Cas13d for RNA targeting in a cancer immunotherapy application!

big thanks to @Nature for featuring our work!!